Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Prevnar 13

Prevnar 13

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Prevnar 13

34 trials tracked of Prevnar 13: 22 in phase 3 or 4 and 4 with published results. The most-cited published study has 42 citations.

34Trials tracked
22Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 21 Phase 2 12
  1. Phase 3 Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) Completed · 42 cited
  2. Phase 3 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) Completed · 15 cited
  3. Phase 3 A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) Completed · 10 cited
  4. Phase 3 Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) Completed · 3 cited
  5. Phase 4 Vaccinating Children After Chemotherapy Completed
  6. Phase 3 Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age Completed
Show 28 more trials
  1. Phase 3 Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) Completed
  2. Phase 3 Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) Completed
  3. Phase 3 A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) Completed
  4. Phase 3 Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants Completed
  5. Phase 3 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) Completed
  6. Phase 3 A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Completed
  7. Phase 3 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) Completed
  8. Phase 3 Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) Completed
  9. Phase 3 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed
  10. Phase 3 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE) Completed
  11. Phase 3 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY) Completed
  12. Phase 3 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed
  13. Phase 3 Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) Completed
  14. Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed
  15. Phase 3 Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029) Completed
  16. Phase 3 Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) Completed
  17. Phase 2 The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002) Completed
  18. Phase 2 Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants Completed
  19. Phase 2 Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children Completed
  20. Phase 2 Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age Completed
  21. Phase 2 Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission Completed
  22. Phase 2 A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003) Completed
  23. Phase 2 A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) Completed
  24. Phase 2 Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) Completed
  25. Phase 2 Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004) Completed
  26. Phase 2 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008) Completed
  27. Phase 2 Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) Completed
  28. Phase 2 A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.